MARKET

MGTA

MGTA

Magenta Therapeutics
NASDAQ

Real-time Quotes | Nasdaq Last Sale

12.04
-0.86
-6.67%
After Hours: 11.97 -0.07 -0.58% 16:16 03/08 EST
OPEN
12.73
PREV CLOSE
12.90
HIGH
12.77
LOW
11.67
VOLUME
554.77K
TURNOVER
--
52 WEEK HIGH
13.54
52 WEEK LOW
5.76
MARKET CAP
584.62M
P/E (TTM)
-6.1718
1D
5D
1M
3M
1Y
5Y
The Daily Biotech Pulse: FDA Nod For Pfizer, Kiniksa Rises On Commercialization Pact With Regeneron, Bio-Techne To Buy Diagnostic Company
Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting 52-week Highs March 3)
Benzinga · 4d ago
Mizuho Securities Remains a Buy on Magenta Therapeutics (MGTA)
SmarterAnalyst · 5d ago
Magenta Therapeutics EPS beats by $0.02
Magenta Therapeutics (MGTA): GAAP EPS of -$0.38 beats by $0.02.Cash, cash equivalents and marketable securities of $148.8MPress Release
Seekingalpha · 5d ago
10-K: MAGENTA THERAPEUTICS, INC.
(EDGAR Online via COMTEX) -- ITEM 7. MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS The following discussion and...
Edgar Online - (EDG = 10Q, 10K) · 5d ago
Magenta Therapeutics Q4 EPS $(0.38) Up From $(0.59) YoY
Magenta Therapeutics (NASDAQ:MGTA) reported quarterly losses of $(0.38) per share. This is a 35.59 percent increase over losses of $(0.59) per share from the same period last year.
Benzinga · 5d ago
BRIEF-Magenta Therapeutics Reports Qtrly Loss Per Share $0.38
reuters.com · 5d ago
Magenta Therapeutics 4Q Loss/Shr 38c >MGTA
Magenta Therapeutics 4Q Loss/Shr 38c >MGTA
Dow Jones · 5d ago
Press Release: Magenta Therapeutics Reports Fourth Quarter and Full-Year 2020 Financial Results and Recent Program Highlights
Dow Jones · 5d ago
More
Forecast
Actual (USD)
Estimate (USD)
Income StatementMore
Net Income (USD)
YoY (%)
Balance SheetMore
Total Assets (USD)
Total Liabilities (USD)
Debt to Asset (%)
Cash FlowMore
Operating (USD)
YoY (%)
Learn about the latest financial forecast of MGTA. Analyze the recent business situations of Magenta Therapeutics through EPS, BVPS, FPS, and other data. This information may help you make smarter investment decisions.
Analyst Rating

Based on 5 analysts

Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

Analyst Price Target
The average MGTA stock price target is 17.00 with a high estimate of 22.00 and a low estimate of 13.00.
EPS
Institutional Holdings
Institutions: 139
Institutional Holdings: 29.44M
% Owned: 60.63%
Shares Outstanding: 48.56M
TypeInstitutionsShares
Increased
35
2.45M
New
15
23.42K
Decreased
24
1.88M
Sold Out
0
0
  • Performance
  • Asset Allocation
  • Dividend History
No Data
Industry
Biotechnology & Medical Research
-2.02%
Pharmaceuticals & Medical Research
-0.50%
Key Executives
Chairman/Independent Director
Michael Bonney
President/Chief Executive Officer/Co-Founder/Director
Jason Gardner
Chief Financial Officer/Chief Operating Officer
Steve Mahoney
Chief Human Resource Officer
Kristen Stants
Senior Vice President
Li Malmberg
Vice President - Finance
Cindy Driscoll
Other
John Davis
Other
Christina Isacson
Secretary
Zoran Zdraveski
Independent Director
Jeffrey Albers
Independent Director
Bruce Booth
Independent Director
Alexis Borisy
Independent Director
Blake Byers
Independent Director
Thomas Daniel
Independent Director
Alison Lawton
Independent Director
Anne McGeorge
Independent Director
Amy Ronneberg
Independent Director
David Scadden
No Data
  • All
  • Financials
  • Insiders
More
About MGTA
Magenta Therapeutics, Inc is a clinical-stage biotechnology company. The Company is developing medicines to bring the curative power of immune reset to more patients with autoimmune diseases, blood cancers and genetic diseases. The Company is developing an integrated platform to change the treatment landscape in both autologous and allogeneic transplant, and provide access to a one-time curative treatment option for more patients with autoimmune diseases, hematologic malignancies and genetic diseases. The Company is also developing a portfolio of biologics, including antibody drug conjugates, small molecules and a cell therapy. The Company’s products include MGTA-145, CD45-ADC, MGTA-456 and MGTA-117.

Webull offers kinds of Magenta Therapeutics Inc stock information, including NASDAQ:MGTA real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, MGTA stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading MGTA stock methods without spending real money on the virtual paper trading platform.